Rating Change
BTIG analysts reiterated a Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) on July 13, 2026.
reiterateNASDAQ:ORKA
BTIG Reiterates Buy Rating on Oruka Therapeutics, Inc. (ORKA)
Rating Change BTIG analysts reiterated a Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) on July 13, 2026. Market Context Oruka Therapeutics, Inc.
Market Context
Oruka Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $84.56 with a market capitalization of $1.1B.
Analyst coverage from BTIG provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Oruka Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Oruka Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 13, 2026 | BTIG | Buy | N/A |
| Jul 01, 2026 | UBS | Buy | N/A |
| Jun 23, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 18, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 14, 2026 | BTIG | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ORKA Stock Page
Frequently Asked Questions
What does a Buy rating mean for ORKA?
A Buy rating from BTIG reflects the analyst's outlook on Oruka Therapeutics, Inc. (NASDAQ:ORKA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ORKA forecast page.